Poster Poster Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

BLUE RIBBON POSTER RADIOPHARMACEUTICALS: Attention Med3D: A 3D Deep Learning Model Based on Transfer Learning and Attention Mechanism for Predicting Mid-Treatment Chemoradiation Response on FDG PET of La-NSCLC

Abstract
Purpose

Accurate assessment of early radiotherapy response in tumors provides crucial guidance for optimizing radiotherapy protocols. We developed a 3D deep learning model termed Attention Med3D based on transfer learning and attention mechanisms for predicting mid-treatment fluorodeoxyglucose (FDG) positron emission tomography (PET) response.

Methods

Twenty-five patients with locally advanced non-small cell lung cancer (LA-NSCLC) underwent baseline FDG-PET/CT imaging (PETpre) and repeat imaging during week 3 (PETmid) of chemoradiotherapy under the FLARE-RT trial (NCT02773238). PETpre and planned radiation dose (Dose) were used as inputs to predict voxel-wise SUV values in the 3D PETmid tumor volume. Data augmentation expanded training samples through rotation, flipping, and random scaling. Attention Med3D adopted an encoder-decoder architecture. The encoder was constructed through transfer learning from the Med3D pre-trained model for feature extraction. A decoder based on skip connections and attention mechanisms was designed to reconstruct spatial dimensions through upsampling and predict voxel-wise SUV values. To quantify treatment response, the relative SUV change (∆SUVratio) was calculated as ∆SUVratio = (SUVpre - SUVmid)/SUVpre. Model performance was evaluated through leave-one-patient-out cross-validation, with root mean square error (RMSE) and mean absolute error (MAE) calculated for both direct SUV prediction and the derived ∆SUVratio.

Results

Attention Med3D achieved tumor voxel-level SUV prediction with RMSE of 1.521 and MAE of 1.240. For the calculated ∆SUVratio, the model achieved an RMSE of 0.265 and MAE of 0.215. The model numerically outperformed 3D U-Net and 3D ResNet series models for both SUV prediction (RMSE: 1.610-1.810; MAE: 1.353-1.515) and calculated ∆SUVratio (RMSE: 0.298-0.346; MAE: 0.249-0.283), though without statistical significance (Friedman test, p > 0.05).

Conclusion

The proposed model leveraged transfer learning to construct a 3D deep learning framework suitable for limited-sample radiotherapy response prediction. This framework has the potential to help clinicians to optimize individualized radiotherapy protocols for lung cancer patients.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested